Longbio Pharma
Clinical trials sponsored by Longbio Pharma, explained in plain language.
-
New injection shows promise for kidney disease patients
Disease control Not yet recruitingThis study tests an investigational drug called LP-005 in 46 adults with complement-mediated kidney disease, a condition where the immune system attacks the kidneys. Participants receive the injection alongside their standard care. The goal is to see if the drug can reduce protei…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for PNH patients: LP-005 shows promise in long-term trial
Disease control Not yet recruitingThis study looks at the long-term safety and effectiveness of an injection called LP-005 in adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. It is for people who already completed an earlier LP-005 study. The goal is to see if LP-005 can help control …
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New shot could shrink nasal polyps and ease breathing
Symptom relief Not yet recruitingThis study tests an experimental drug called LP-003 for people with long-term sinus inflammation and nasal polyps (growths in the nose). The goal is to see if it can shrink polyps and reduce stuffiness. About 150 adults will receive either the drug or a placebo, and their progres…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC